Skip to Content

Triumeq Approval History

FDA Approved: Yes (First approved August 22, 2014)
Brand name: Triumeq
Generic name: abacavir, dolutegravir and lamivudine
Dosage form: Tablets
Company: ViiV Healthcare
Treatment for: HIV Infection

Triumeq (abacavir, dolutegravir and lamivudine) is a fixed-dose combination containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine for the treatment of HIV-1 infection.

Development History and FDA Approval Process for Triumeq

DateArticle
Aug 22, 2014Approval FDA Approves Triumeq for the Treatment of HIV-1 Infection

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide